MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Merck & Co. ROA Ratio 2011-2026 | MRK
Annual ROA Ratio Merck & Co.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.34 | 14.62 | 0.34 | 13.3 | 12.35 | 7.72 | 11.66 | 7.53 | 2.72 | 4.11 | 4.36 | 12.12 | 4.17 | 5.81 | 5.97 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.62 | 0.34 | 8.01 |
Quarterly ROA Ratio Merck & Co.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.33 | 15.71 | 16.44 | 16.47 | 8.07 | 5.84 | 4.38 | 2.96 | 12.72 | 11.11 | 16.0 | 13.81 | 15.51 | 10.09 | 13.3 | 11.63 | 13.2 | 10.0 | 12.26 | 11.3 | 11.18 | 8.87 | 11.23 | 11.34 | 10.24 | 5.32 | 5.25 | 2.83 | 2.98 | 3.92 | 6.21 | 8.56 | 7.61 | 4.73 | 6.53 | 6.03 | 5.45 | 3.41 | 4.32 | 3.43 | 4.8 | 4.68 | 5.75 | 5.9 | 4.72 | 3.43 | 5.06 | 5.62 | 6.46 | 4.96 | 6.57 | 6.55 | 6.78 | 4.53 | 1.61 | 1.93 | 0.99 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.47 | 0.99 | 7.82 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioLineRx Ltd.
BLRX
|
-33.24 | $ 2.25 | 1.81 % | $ 908 M |  Israel |
 |
BioNTech SE
BNTX
|
65.02 | $ 91.28 | 0.11 % | $ 27.2 B |  Germany |
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M | Germany |
 |
Alnylam Pharmaceuticals
ALNY
|
6.32 | $ 330.34 | 3.6 % | $ 43.3 B |  USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-88.77 | $ 0.44 | -16.64 % | $ 5.04 M | Israel |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
Catalyst Pharmaceuticals
CPRX
|
19.41 | $ 24.98 | 1.17 % | $ 3.05 B | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-46.69 | $ 10.14 | -0.29 % | $ 135 M | USA |
 |
Cardiff Oncology
CRDF
|
-74.09 | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
-37.97 | $ 0.53 | -3.07 % | $ 6.98 M | USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-41.32 | $ 37.7 | 1.26 % | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-25.67 | $ 49.15 | -0.73 % | $ 4.42 B |  Schweiz |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-44.67 | $ 2.96 | -1.0 % | $ 252 M | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
CytomX Therapeutics
CTMX
|
-11.46 | $ 4.4 | -3.51 % | $ 607 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Citius Pharmaceuticals
CTXR
|
-33.8 | $ 0.86 | 0.67 % | $ 5.79 M | USA |
 |
Cue Biopharma
CUE
|
-63.02 | $ 0.18 | -1.61 % | $ 17.1 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-140.01 | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-206.44 | - | 10.36 % | $ 9.8 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.23 | $ 4.09 | -0.97 % | $ 437 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-31.93 | $ 4.15 | -32.52 % | $ 10.4 M | USA |
 |
Daré Bioscience
DARE
|
-41.26 | $ 1.81 | 4.02 % | $ 20.2 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-62.87 | $ 20.36 | -3.32 % | $ 2.84 B | France |
 |
Aravive
ARAV
|
-122.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-24.26 | $ 8.22 | 2.37 % | $ 225 M | Israel |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Denali Therapeutics
DNLI
|
-30.77 | $ 19.38 | -6.15 % | $ 3.19 B | USA |
 |
Dyadic International
DYAI
|
-74.05 | $ 0.87 | -2.8 % | $ 31.5 M | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-44.38 | $ 31.37 | 1.0 % | $ 2.08 B | USA |
 |
Avenue Therapeutics
ATXI
|
-99.25 | - | -52.27 % | $ 4.45 M | USA |